| Autor: |
W, Kuhn, B, Schmalfeldt, L, Pache, K, Späthe, K, Ulm, K, Renziehausen, H, Nöschel, E, Canzler, B, Richter, M, Kroner, G, Tilch, F, Janicke, H, Graeff |
| Rok vydání: |
1998 |
| Předmět: |
|
| Zdroj: |
International journal of oncology. 13(1) |
| ISSN: |
1019-6439 |
| Popis: |
Primary therapy of advanced ovarian cancer is standardized, the therapy in relapsed ovarian cancer however is still controversial. In a prospective study the benefit of secondary surgery and/or second-line chemotherapy were evaluated. 139 patients with relapsed ovarian cancer were stratified according to a treatment plan: patients with early relapse (recurrence-free interval 12 months) or primary progression during chemotherapy (n=43) were treated chemotherapeutically with etoposide (p.o. vs. i.v.). Patients with late relapse (recurrence-free interval12 months, n=96) were referred, if possible, to a secondary debulking operation, followed by a platinum-based chemotherapy. Remission-rate, toxicity and survival time were analyzed. Median survival time in theearly relapsegroup was 15 months compared to 30 months in patients with late relapse (p=0.0004). Within thelate relapsegroup patients with secondary debulking and chemotherapy (n=59) had a statistically significant survival advantage compared to patients who had only chemotherapy (n=37) (38 vs. 12 months, p0.0001). The unfavorable group of patients with early relapse should be treated chemotherapeutically, whereas in patients with late relapse a secondary debulking seems to improve prognosis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
